Evidence map›Paper›PMID 31613888›Full record

ArticlePloS one2019

Risk factor-based subphenotyping of heart failure in the community.

Charlotte Andersson, Asya Lyass, Vanessa Xanthakis, Martin G Larson, Gary F Mitchell, Susan Cheng, Ramachandran S Vasan

Abstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. The genetics of cardiac amyloidosis.Heart failure reviews · 2022
    Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Charlotte AnderssonThe Framingham Heart Study, Framingham, Massachusetts, United States of America.ORCID 0000-0001-6019-8627
Asya LyassThe Framingham Heart Study, Framingham, Massachusetts, United States of America.
Vanessa XanthakisThe Framingham Heart Study, Framingham, Massachusetts, United States of America.
Martin G LarsonThe Framingham Heart Study, Framingham, Massachusetts, United States of America.
Gary F MitchellCardiovascular Engineering, Inc., Norwood, Massachusetts, United States of America.
Susan ChengThe Framingham Heart Study, Framingham, Massachusetts, United States of America.
Ramachandran S VasanThe Framingham Heart Study, Framingham, Massachusetts, United States of America.

Funding

FRAMINGHAM HEART STUDY - YEAR 5 EXAM75N92019D00031 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI RAMACHANDRAN, VASAN · 2019 to 2024
$29.8M
Ventricular Vascular Coupling: Correlates and PrognosisR01HL080124 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI RAMACHANDRAN, VASAN S · 2005 to 2009
$3.4M
Mediators of Systemic Inflammation and Heart Failure Risk in the CommunityR01HL143227 · NHLBI · CEDARS-SINAI MEDICAL CENTER · PI CHENG, SUSAN · 2019 to 2022
$3.3M
Ventricular-vascular coupling in the elderly: lifecourse determinants, trajectories, and prognostic significanceR01HL142983 · NHLBI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CHENG, SUSAN, MITCHELL, GARY FRANK · 2019 to 2022
$3.2M
Vascular Stiffness as a Precursor of Hypertension in a Middle-aged CohortR01HL126136 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MITCHELL, GARY FRANK, RAMACHANDRAN, VASAN S · 2015 to 2018
$2.6M
Ventricular Matrix Remodeling: Correlates and PrognosisR01HL067288 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI RAMACHANDRAN, VASAN S. · 2001 to 2004
$870k
Genetics of Oxidative Stress in Ventricular RemodelingR01HL071039 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI RAMACHANDRAN, VASAN S. · 2002 to 2003
$252k
THE FRAMINGHAM HEART STUDY-N01HC25195-268025195-268025195N01HC025195 · HC · TRUSTEES OF BOSTON UNIVERSITY · PI WOLF, PHILIP A · 2002 to 2006
–
NHLBI NIH HHS 75N92019D00031NHLBI NIH HHS HHSN268201500001CNHLBI NIH HHS HHSN268201500001INHLBI NIH HHS N01 HC025195NHLBI NIH HHS R01 HL067288NHLBI NIH HHS R01 HL071039NHLBI NIH HHS R01 HL077477NHLBI NIH HHS R01 HL080124NHLBI NIH HHS R01 HL126136NHLBI NIH HHS R01 HL142983NHLBI NIH HHS R01 HL143227
6 · The paper itself

Abstract

backgroundHeart failure (HF) is a heterogeneous clinical syndrome with varying prognosis. Subphenotyping of HF is a research priority to advance our understanding of the syndrome. We formulated a subphenotyping schema and compared long-term mortality risk among the HF subphenotypes in the community-based Framingham Study. METHODS AND

resultsIn hierarchical order, we grouped participants with new-onset HF (stratified by HF with reduced [HFrEF] vs. preserved ejection fraction [HFpEF]) according to the presence of: (1) coronary heart disease (CHD), (2) metabolic syndrome (MetS), (3) hypertension, and (4) 'other' causes. Age at HF onset was lowest in people with the MetS (mean 76 vs. 77 years for HFrEF and HFpEF, respectively) and highest in those with hypertension only (mean 82 and 85 years for HFrEF and HFpEF, respectively). For HFrEF, 10-year cumulative mortality and hazards ratios [HR] were 87% for CHD (n = 219; referent group), 88% for MetS (n = 105; HR 0.95 [95% CI 0.73-1.23]), 82% for hypertension (n = 104; HR 0.71 [0.55-0.91]), and 78% for other (n = 37; HR 0.81 [0.55-1.19]). Corresponding 10-year cumulative mortality and HR data for HFpEF were: 85% for CHD (n = 84; referent), 83% for MetS (n = 118; HR 0.98 [0.72-1.33]), 81% for hypertension (n = 127; HR 0.71 [0.52-0.95]), and 76% for other (n = 43; HR 0.76 [0.50-1.14]). In a sample without overt heart failure (n = 5536), several echocardiographic and vascular indices showed graded worsening of age- and sex adjusted-values among those having CHD, MetS, hypertension, or obesity, compared with individuals not having these risk factors.

conclusionsHF subphenotypes characterized by the presence of CHD or metabolic syndrome present at a younger age and are marked by greater mortality risk. The clinical utility of the proposed subphenotyping schema warrants further research.

Indexed as

AgedAged, 80 and overAge FactorsCohort StudiesCoronary DiseaseEchocardiographyFemaleHeart FailureHumansHypertensionMaleMetabolic SyndromePhenotypePrognosisProportional Hazards ModelsRisk Factors

Identifiers

PMID31613888
PMCPMC6793865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.